Brain+ (BRAINP.CO) Stock Analysis & AI Equity Report
Brain+ (BRAINP.CO) overview
Brain+ (BRAINP.CO) stock analysis and AI equity research. For the latest completed financial year, 2023, Brain+ reported revenue of DKK 2.4m and operating profit of DKK -17.5m; the year-end share price was 0.19 DKK and market capitalisation was DKK 7.6m. Brain+ is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Brain+'s valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2025-09-05. Data will be refreshed during report generation.
About Brain+
Brain+ A/S develops digital healthcare software for dementia care. Its main offering is the Ayla platform and Ayla CST assistant, which deliver cognitive stimulation therapy and related tools for healthcare providers, patients, and carers. The company focuses on software-based treatment and care solutions for cognitive decline, with sales in Denmark and the United Kingdom.
Generate the Brain+ report
Brain+ is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Brain+ and represent the latest completed financial year (2023). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.